Enliven Therapeutics Inc [ELVN] stock is trading at $24.15, up 1.22%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ELVN shares have gain 7.33% over the last week, with a monthly amount drifted -5.00%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enliven Therapeutics Inc [NASDAQ: ELVN] stock has seen the most recent analyst activity on December 13, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $42. Previously, H.C. Wainwright started tracking the stock with Buy rating on September 09, 2024, and set its price target to $37. On June 11, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $32 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $34 on April 09, 2024. Jefferies initiated its recommendation with a Buy and recommended $27 as its price target on March 29, 2023.
Enliven Therapeutics Inc [ELVN] stock has fluctuated between $10.90 and $30.03 over the past year. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Enliven Therapeutics Inc [NASDAQ: ELVN] shares were valued at $24.15 at the most recent close of the market. An investor can expect a potential return of 63.56% based on the average ELVN price forecast.
Analyzing the ELVN fundamentals
Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -228.15%, Pretax Profit Margin comes in at -193.14%, and Net Profit Margin reading is -193.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.29 and Total Capital is -0.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.50 points at the first support level, and at 20.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.02, and for the 2nd resistance point, it is at 25.88.
Ratios To Look Out For
For context, Enliven Therapeutics Inc’s Current Ratio is 17.44. Further, the Quick Ratio stands at 17.44, while the Cash Ratio is 5.91.
Transactions by insiders
Recent insider trading involved Hohl Benjamin, CHIEF FINANCIAL OFFICER, that happened on Jan 03 ’25 when 1000.0 shares were sold. Officer, Patel Anish completed a deal on Jan 07 ’25 to buy 28367.0 shares. Meanwhile, Officer Hohl Benjamin bought 1000.0 shares on Jan 03 ’25.
